Original articlesThoracic tumorsLarge scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions
Thoracic tumors
Under an Elsevier user license
open archive
Key words
EGFR mutations
NSCLC
tyrosine-kinase inhibitors (TKIs)
liquid biopsy
Cited by (0)
Copyright © 2017 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.